Trace the evolution of India's National Biotechnology Development Strategy (NBDS) and discuss its key…

Question

Trace the evolution of India's National Biotechnology Development Strategy (NBDS) and discuss its key objectives. Critically evaluate its impact on the growth of the biotechnology sector in India.

Ghissu Editorial · Accepted Answer

India's biotechnology strategy evolved from DBT (1986) through the first NBDS (2007), BIRAC (2012) and NBDS 2021-25 to the BioE3 Policy, aiming to expand research and bio-manufacturing. The bioeconomy has crossed $165 billion, but R&D spending of about 0.65% of GDP, regulatory delays and talent gaps limit its impact.

**Introduction**

India’s National Biotechnology Development⟦1⟧ Strategy (NBDS) has evolved to harness biotechnology for economic growth, healthcare, agriculture, and sustainability, supporting a $165 billion bioeconomy and national priorities like Atmanirbhar Bharat. It provides a coherent framework to address challenges and maximize socio-economic benefits through innovation and policy support.

**Strategic Objectives and Outcomes**

SKETCH: timeline | Evolution of NBDS  
- 1986 :: Establishment of Department of Biotechnology (DBT)  
- 2007 :: First National Biotechnology Development Strategy
- 2012 :: Launch of Biotechnology Industry Research Assistance Council (BIRAC)
- 2015 :: NBDS 2015-2020 launched  
- 2021 :: National Biotechnology Development Strategy 2021-25 introduced  
- 2024 :: Approval of BioE3 Policy⟦2⟧ followed by the Biopharma SHAKTI initiative

1. **Research and Innovation**: NBDS expands research via Bio-RIDE, Emerging Frontiers in Biotechnology, and DBT North Eastern Programme⟦3⟧, supporting 150+ projects in 21 states, including ==Andhra Pradesh⟦5⟧⟦4⟧’s research institutions==, strengthening genomics and bio-manufacturing. This has enhanced India’s global competitiveness in biotech sectors like bioinformatics and synthetic biology.

2. **Economic Growth and Jobs**: The BioE3 Policy and Biopharma SHAKTI (Rs. 10,000 crore) target a $300 billion bioeconomy by 2030, fostering startups and manufacturing, with India leading in vaccine production. These initiatives have created millions of skilled jobs and boosted exports, reinforcing India’s position as a global biotech hub.

**Challenges**

2. **Infrastructure and Funding Gaps**: R&D spend is low (~0.65% GDP), slowing the translation of biotech advances into products and public health benefits. Limited BSL-4 labs and clinical trial sites constrain advanced research and commercialization.

**Way Forward**

1. **State-Centre Collaboration**: Strengthen State S&T Councils and BioE3 Cells, including ==Andhra Pradesh’s research bodies==, for regional biotech adoption. This will tailor innovations to local needs and enhance resource utilization.

2. **Regulatory Streamlining and Skill Development**: Harmonize laws with clear ethics, boost funding, and expand training to retain talent. Programs like BIRAC should be scaled to support startups and reduce brain drain.

**Conclusion**

NBDS has catalyzed India’s biotech growth but requires regulatory reform, infrastructure investment, and enhanced skill development to sustain momentum and fully realize its socio-economic potential.

Model answer

ఈ ప్రశ్నను ప్రాక్టీస్ చేయండి

Ghissu